Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry

Therapeutic Drug Monitoring

Volumn 26, Issue 6, 2004, Pages 650-657

  Keevil, Brian G ^a   Newman, Sheila ^a   Lockhart, Stephen ^a   Howard, Susan J ^b   Moore, Caroline B ^b   Denning, David W ^a,b,c  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b HOPE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Aspergillosis; Tandem mass spectrometry; Voriconazole

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; CARBON; FORMIC ACID; KETOCONAZOLE; METHANOL; VORICONAZOLE; ZINC SULFATE;

ARTICLE; BIOASSAY; CENTRIFUGATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; REGRESSION ANALYSIS; SUPERNATANT; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MASS SPECTROMETRY; PYRIMIDINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRIAZOLES;

EID: 9644258580     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200412000-00011     Document Type: Article

References (11)

1. Denning DW, Ribaud P, Milpied N, et al. The efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-571.
2. Herbrecht R, Denning DW, Patterson TF, et al. Randomised comparison of voriconazole and amphotericin B in primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
3. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31:540-547.
4. Voriconazole FDA briefing document. Oct 2001. http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3792b2_01_Pfizer.pdf
5. Boyd AE. Modi S, Moore CB, et al. Adverse drug reactions to the new triazole, voriconazole - the need for therapeutic monitoring. Abstract Federation of Infection Societies Annual Meeting, Manchester, November 2001.
6. Potoski BA, Brown J. The safety of voriconazole. Clin Infect Dis. 2002; 35:1273-1275.
7. Perea S, Pennick GJ, Modak A, et al. Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother. 2000;44:1209-1213.
8. Zhou L, Glickman RD, Chen N, et al. Determination of voriconazole in aqueous humour by liquid chromatography-electrospray ionization-mass spectrometry. J Chromatogr B. 2002;776:213-220.
9. Law D, Moore CB, Denning DW. Discrepancies associated with the measurement of itraconazole serum concentrations by biossay. J Antimicrob Chemother. 1999;44:577-582.
10. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther. 1995;57:662-669.
11. Guidance for Industry. Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), 2001.